Biotechnology company Genentech, part of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Friday that it has secured US Food and Drug Administration (FDA) approval for its Vabysmo (faricimab-svoa) prefilled syringe for treating three retinal conditions that can cause blindness.
The Vabysmo 6.0 mg single-dose prefilled syringe (PFS) is indicated for use in the treatment of wet, or neovascular, age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). Together, these three conditions affect almost three million people in the United States.
Designed to simplify administration, Vabysmo PFS offers retina specialists a ready-to-use option. It delivers the same medication as existing Vabysmo vials.
Vabysmo has already gained approval in over 95 countries for wet AMD and DME, with RVO approvals in selected regions.
Xylyx Bio receives SBIR grant from NIDDK
Lilly expands manufacturing footprint in Ireland
Arecor reports positive Phase I Results for AT278 insulin at EASD 2024
Diamyd Medical seeks Fast-Track approval for Type 1 Diabetes immunotherapy
Biosergen completes first successful BSG005 treatment in invasive fungal trial
Hyundai Bioscience to conduct Phase 3 trial for high-risk COVID-19 patients
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
Lifecare sensor achieves 9-week longevity in dog trial
RedHill Biopharma reports promising results for opaganib in obesity and diabetes studies
Sumitomo Pharma and Poxel report positive results from TWYMEEG study in Japan
Sapphiros names new chief financial officer
Amylyx receives EU Orphan Drug Designation for Wolfram syndrome treatment
KVK Tech registers Lomaira 8mg tablets in Mexico
GSK's Arexvy receives positive CHMP opinion for at-risk adults aged 50-59
M8 Pharmaceuticals signs exclusive licensing and distribution agreement with LG Chem